Protalix BioTherapeutics (Protalix BioTherapeutics) Cash Flow from Financing : $24.67 Mil (TTM As of Dec. 2023)

Protalix BioTherapeutics Cash Flow from Financing Chart

Protalix BioTherapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Cash Flow from Financing		Get a 7-Day Free Trial					-	46.47	12.08	8.24	24.67

Protalix BioTherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial															4.08	14.23	10.43	-	-

Protalix BioTherapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Protalix BioTherapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Protalix BioTherapeutics's Cash from Financing for the quarter that ended in Dec. 2023 is:

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics  (AMEX:PLX) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Protalix BioTherapeutics's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Protalix BioTherapeutics's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Protalix BioTherapeutics's net issuance of debt for the three months ended in Dec. 2023 was $0.00 Mil. Protalix BioTherapeutics received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Protalix BioTherapeutics's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Protalix BioTherapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Protalix BioTherapeutics's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Protalix BioTherapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Protalix BioTherapeutics's other financing for the three months ended in Dec. 2023 was $0.00 Mil. Protalix BioTherapeutics received $0.00 Mil on other financial activities.

Protalix BioTherapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description